Related Experiment Video
Updated: Jan 13, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Novel 1-(2-Aryl-2-adamantyl)piperazine Derivatives Exhibit In Vitro Anticancer Activity Across Various Human Cancer
Irida Papapostolou1,2, Evangelia Sereti2,3, Stavroula Chatira2
1Department of Biochemistry and Molecular Medicine, Faculty of Medicine, University of Bern, 3012 Bern, Switzerland.
Abstract:
Background and Objectives: Cutaneous melanoma (CM) is widely regarded as the most aggressive form of skin cancer worldwide, showing a rising global incidence. It develops from the uncontrolled transformation of pigment-producing melanocytes. The aim of this study is to characterize the cytotoxic and anti-proliferative properties of two 1-(2-aryl-adamantyl)piperazine derivatives, 6 and 7, with a specific emphasis on their impact on melanoma cells. Both compounds are synthesized based on the adamantane core structure which increases drug-like properties of the lead compound phencyclidine I, without increasing toxicity. Materials and Methods: This study describes concentration-dependent effects on cell viability and clonogenicity. Results: SRB assays, clonogenic (long-term) assays, and scratch assays reveal a significant anticancer activity of these two agents at low μΜ levels with a selective activity against melanoma cells. Furthermore, Western blot experiments indicate that both 6 and 7 induce LC3 accumulation, procaspase 3 decrease, and PARP cleavage, suggesting the implication of multiple death pathways in their anticancer mechanism of action. Conclusions: This study sheds light on the in vitro anticancer potential of two novel 1-(2-aryl-2-adamantyl)piperazine derivatives. It highlights their differential activity against melanoma and emphasizes their potential as lead candidates for further therapeutic exploration.
Insights
Two novel adamantane derivatives show significant anticancer activity against melanoma cells. These compounds exhibit selective cytotoxicity and induce multiple cell death pathways, indicating potential for new melanoma therapies.
Area of Science:
- Pharmacology
- Oncology
- Medicinal Chemistry
Background:
- Cutaneous melanoma (CM) is an aggressive skin cancer with increasing global incidence.
- CM arises from the uncontrolled proliferation of melanocytes.
- Developing novel therapeutic agents for CM is a critical unmet need.
Purpose of the Study:
- To evaluate the cytotoxic and anti-proliferative effects of two novel 1-(2-aryl-adamantyl)piperazine derivatives, compounds 6 and 7.
- To investigate the mechanism of action of these compounds in melanoma cells.
- To assess their potential as lead candidates for melanoma treatment.
Main Methods:
- Synthesis of 1-(2-aryl-adamantyl)piperazine derivatives (6 and 7).
- In vitro assessment of cell viability (SRB assay) and clonogenicity.
- Analysis of cell proliferation and migration (scratch assay).
- Western blot analysis to investigate cell death pathway markers (LC3, procaspase 3, PARP).
Main Results:
- Compounds 6 and 7 demonstrated significant anticancer activity at low micromolar concentrations.
- Selective cytotoxicity against melanoma cells was observed.
- Induction of LC3 accumulation, procaspase 3 decrease, and PARP cleavage suggests involvement of multiple cell death pathways.
Conclusions:
- Novel 1-(2-aryl-adamantyl)piperazine derivatives exhibit promising in vitro anticancer potential against melanoma.
- Compounds 6 and 7 display selective activity and induce apoptosis and autophagy-related markers.
- These findings support their further investigation as lead compounds for melanoma therapy.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...